Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat.
In toxicity studies, compound-induced changes are typically evaluated using a combination of endpoints and there are often a number of potential markers in biological fluids which can indicate toxic change in tissues and organs. However, some biomarkers are not specific to the organ of injury and therefore there is a continuing search for more sensitive and specific indicators of target organ toxicity. In experiments to assess the potential diagnostic usefulness of surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, skeletal muscle toxicity was induced in Wistar Han rats by administering 2,3,5,6-tetramethyl-p-phenylenediamine (TMPD). The skeletal muscle toxicity was monitored using established endpoints such as increase in serum aldolase (Aldol), aspartate aminotransferase (AST) and histopathology, and also using SELDI retentate chromatography mass spectrometry of urine samples. Clear differences in urinary protein patterns between control and TMPD-treated animals were observed on the ProteinChip surfaces. Additionally a specific urine marker protein of 11.8 kDa was identified in TMPD-dosed rats, and the detection of the marker was related to the degree of skeletal muscle toxicity assessed by recognized clinical pathology endpoints. The 11.8 kDa protein was identified as parvalbumin-alpha. These experiments demonstrated the potential of urinary parvalbumin-alpha as a specific, noninvasive, and easily detectable biomarker for skeletal muscle toxicity in the rat and the potential of SELDI technology for biomarker detection and identification in toxicology studies.
Dare
Theo O
TO
Clinical Pathology, Cellular and Biochemical Toxicology, Safety Assessment, GlaxoSmithKline Research and Development, Ware, Hertfordshire, UK. tod33742@gsk.com
Davies
Huw A
HA
Turton
John A
JA
Lomas
Lee
L
Williams
Thomas C
TC
York
Malcom J
MJ
D000818:Animals; D015415:Biomarkers / Q000652:urine; D004798:Enzymes / Q000097:blood; D005260:Female; D007834:Lasers; D008297:Male; D018482:Muscle, Skeletal / Q000737:chemistry / Q000187:drug effects* / Q000293:injuries; D010320:Parvalbumins / Q000652:urine*; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods; D051381:Rats; D017208:Rats, Wistar; D013499:Surface Properties; D013772:Tetramethylphenylenediamine / Q000633:toxicity
D015415:Biomarkers; D004798:Enzymes; D010320:Parvalbumins; D013772:Tetramethylphenylenediamine